Clinical Trial

Fluorescein Angiography in Patients With Diabetes and Chronic Kidney Disease

Study acronym: Fluo-AKI
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 7, 2025 (before its estimated October 10, 2025 completion). Its status may not reflect the trial's current state.
Summary
Our study hypothesizes that fluorescein exposure in diabetic patients with advanced chronic kidney disease results in deterioration of kidney function. It will therefore aim to evaluate the incidence of acute kidney injury induced by fluorescein in diabetic patients with CKD. The objective is to determine the incidence, severity and risk factors associated with this deterioration to improve the care of this specific population.
Trial Details
NCT Number NCT06760650
Lead Sponsor Saint-Joseph University
Conditions Chronic Kidney Disease Stage 4, Chronic Kidney Disease Stage 3B, Chronic Kidney Disease Stage 5, Diabetes Mellitus, Fluorescein Angiography, Acute Kidney Injury
Enrollment 35 participants
Start Date 2025-01-07
Primary Completion 2025-10-10 (estimated)
Study Completion 2025-10-10 (estimated)
Updated on ClinicalTrials.gov 2025-01-07